explore -WSS

explore

author：fashion 2025-09-28 21:06:24 - browse：28

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： CDC advisers recommend seasonal use of Pfizer RSV shot

focus

WSS

UnitedHealth quietly bought dozens of outpatient centers

The drug industry has found itself all alone in Washington

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

What Congress can do to address the rural doctor shortage

With psoriasis trial ahead, Alumis raises $259 million

Biotech stock slump in 2023: awaiting the turnaround

focus

explore

knowledge

Hollywood unions extend contract negotiations for actors

How to bring more disabled researchers into academia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Changes to biosimilar regulatory framework must prioritize patients

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

What does generative AI mean for health care? We asked experts

Precocious puberty in girls comes with mental health risks

Alkermes shareholders re

Precocious puberty in girls comes with mental health risks

focus

Why are Kaiser Permanente staff considering a strike?

IVF, abortion rights issues kick off Biden’s State of the Union

With psoriasis trial ahead, Alumis raises $259 million

Hearing on Medicare drug price negotiation gets unusually heated

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

A deep dive into Applied Therapeutics’ data, and questions on Cassava

hotspot

focus

focus

hotspot